Matthew Gall
CIK 1816194 · Chief Financial Officer · last filed 2026-05-05
Matthew Gall is a Chief Financial Officer who has filed 16 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for TNGX, was dated May 5, 2026. Across all open-market trades the lifetime net is −$21.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.24M
3
16
-$21.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TNGX | Chief Financial Officer | 40,000 | $30.94 | $1.24M | $0 | 1 | 2026-05-05 |
| KLRS | Chief Financial Officer | — | $4.33 | — | $0 | 2 | 2026-03-20 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Chief Financial Officer | 0 | $10.15 | $0 | -$21.3K | 13 | 2025-08-29 |
Recent Filings
16 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-05 | TNGX | Grant (A) | +40,000 | $0 | EDGAR |
| 2026-03-20 | KLRS | Grant (A) | — | $0 | EDGAR |
| 2025-11-03 | KLRS | Grant (A) | — | $0 | EDGAR |
| 2025-08-29 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | −89,429 | $0 | EDGAR |
| 2025-03-11 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | +24,000 | $0 | EDGAR |
| 2024-11-19 | iTeos Therapeutics, Inc. (ITOS) Delisted | Buy (P) | +5,000 | $38.6K | EDGAR |
| 2024-03-08 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-07 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | +41,000 | $0 | EDGAR |
| 2023-10-12 | iTeos Therapeutics, Inc. (ITOS) Delisted | Buy (P) | +5,000 | $41.8K | EDGAR |
| 2023-03-10 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |